Ipca Laboratories Ltd Q1 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/2uzwvekin1it10siolfrsk7f.pdf

Key Takeaways


Domestic Formulation: The Standout Engine


Export & API: The Drag on Performance


Margins: Beating Guidance with Mix and Cost Discipline


Unichem Integration: Early Gains, Long Road Ahead

A.K. Jain: "Nothing is going to come very quickly because a lot of work are happening, the other compilations are going on. They will be filed with regulators. And once they review and whatever their queries are there, that replied, only after then, we will get the approvals and then marketing preparations, all that. So, it's a 1.5 to 2 years kind of journey."

U.S. Generics: A Constructive Environment, Gradual Build

A.K. Jain: "So, there is not much of pricing pressure. Its only marginal pressures are there. But otherwise, let's say, the U.S. is a good market, and we are not seeing that kind of bloodbath now. So, it's a better time for this generic business overall."

Guidance & Commitments

CommitmentSpecificsTimeline
Standalone revenue growth~9% (revised down from 10.5-11%)FY25 full year
Q2 standalone growthDeliver 10.5-11% growth rateQ2 FY25
Standalone EBITDA margin20.5-21% (upside of 0.5-1 pp vs earlier ~21% guide)FY25 full year
Consolidated EBITDA margin~18.5% (upside of 0.5-1 pp vs earlier ~18% guide)FY25 full year
U.S. product launches5-6 total launches (2 done, 3-4 more)FY25
U.S. product launches6-7 additional launchesFY26
New pain division launchDivision deployed in marketWithin 2 months
Australia/NZ revenue recoverySupplies resume, revenue from Q3Q2-Q3 FY25
Unichem double-digit growthAchieve double-digit growth rateNo date (aspiration)

Key Metrics

MetricQ1 FY25
Standalone revenue growth~5%, lower than guidance of 10.5% to 11%
Domestic formulation growth~12%
Export formulation revenue₹395 cr, decline of 1% from ~₹398 cr in Q1 FY24
API business revenue~₹287 cr, decline of 2% from ₹295 cr in Q1 FY24
Standalone EBITDA margin22.25%, better than guidance of 21% for FY25
Consolidated EBITDA margin~18.52%, better than guidance of ~18% for FY25
Full-year standalone revenue growth guidance~9%, revised from earlier projection of 10.5% to 11%
Full-year standalone EBITDA margin guidance20.5% to 21%, with possibility of 0.5 to 1 basis point improvement
Full-year consolidated EBITDA margin guidance~18.5%
IPCA IQVIA growth (Q1 FY25)15%, versus IPM growth of ~9%
Acute segment growth (IQVIA)~12%, versus IPM acute growth of ~8%
Chronic segment growth (IQVIA)~20%, versus IPM chronic growth of 11%
Market share (MAT June 2024)~2.01%, up from 1.91% in MAT June 2023
Market share (Q1 FY25)~2.17%, up from 2.06% in Q1 FY24, a gain of ~11 bps
MR strength~6,500, up from a little less than 6,000 last year
MR productivity per month~₹4.52 lakhs, up from ₹4.21 lakhs in Q1 last year
Australia/New Zealand revenue decline~₹40 cr decline in Q1 FY25
U.S. products launched (cumulative, current FY)5 to 6 products expected by year-end; 2 already launched
U.S. products launched (cumulative, next 2 years)12 to 13 products expected
Unichem U.S. air freight share17% to 18%, reversed from earlier 60% air and 40% sea
Sea freight cost increase~3x